A primary care physician plays a vital role in the overall health of an individual. In most cases, primary care physicians are the first medical professionals that patients talk to about non-life-threatening medical conditions or concerns. Primary care physicians sometimes are referred to as general practitioners because their responsibilities involve all types of health concerns.
During annual visits or other appointments, primary care physicians may order blood work to assess a patient’s health. Should those test results identify abnormalities, primary care physicians may refer patients to see a specialist called a hematologist.
Regional Cancer Care Associates (RCCA) provides comprehensive care for both cancers and non-cancerous blood disorders to patients throughout New Jersey, Connecticut, Maryland, and the Washington, D.C. area.
Hematology is the medical specialty focused on blood, blood-forming organs such as bone marrow, and blood-related disorders and diseases. Hematologists are highly trained physicians whose area of expertise is the blood and blood components. Hematologists generally complete a residency during medical school in internal medicine before going on to advanced training, called a fellowship, in hematology. Unlike oncologists, many, but not all, hematologists, complete fellowship programs that encompass training in both medical oncology as well as hematology.
A hematologist is a medical specialist who diagnoses and treats blood-related disorders, whether they are benign (non-cancerous) or malignant (cancerous). These conditions include issues like blood clots that can block normal blood flow or disorders that lead to excessive bleeding. Hematologists assess your symptoms that may range from mild to severe and use specialized tests and treatments from blood infusion to chemotherapy to blood & marrow transplant to manage these blood conditions, aiming to improve blood health and your overall well-being.
A primary care physician may refer a patient to a hematologist for any one of many reasons. Typically, however, the primary care provider wants to draw on the specialist’s expertise to provide the patient with the most accurate diagnosis and, if necessary, best treatment plan. For example, if a primary care physician orders blood work and the results show an abnormally high or low level of red blood cells, or indications of a problem with blood clotting (known medically of “coagulation”), the physician may want the patient to be evaluated by a hematologist. If a hematologist does diagnose a blood disorder, that specialist will have the knowledge necessary to treat it. In many cases, however, the hematologist is able to rule out a blood disorder or to identify a condition that can be managed by the primary care provider.
Being referred to a blood oncologist does not necessarily mean that a patient has a serious illness. Instead, it means there were concerning irregularities in the patient’s blood test results that need to be investigated. During an appointment with a hematologist, the specialist typically will:
If the hematologist makes a diagnosis, he or she will explain it to the patient and discuss treatment options.
No, seeing a hematologist doesn’t mean you have cancer. Hematologists treat all kinds of blood diseases. . While hematologists do specialize in treating leukemia, lymphoma, and other malignant blood cancers, their area of expertise encompasses all kinds of blood disorders, both cancerous and noncancerous. Patients should ask their primary care provider why they are being referred to a hematologist. While a full evaluation will be required to provide a definitive diagnosis, the primary care provider may be able to allay a patient’s concerns by explaining that the reason for referral is not suspicion of a cancerous condition.
The types of blood cancer & blood disorders that a hematologist is qualified to diagnose and treat include:
The types of noncancerous hematologic conditions that a hematologist oncologist is qualified to diagnose and treat include the following:
Primary care physicians who notice abnormalities in their patients’ blood work may refer those patients to the hematology care team at Regional Cancer Care Associates. Known for their extensive knowledge and experience, the fellowship-trained hematologists of RCCA can accurately diagnose and effectively treat both cancerous and noncancerous hematologic conditions. Every patient who walks through the doors at Regional Cancer Care Associates is greeted with kindness and respect. After meeting with patients and determining his or her condition, specialists create an appropriate treatment plan, using the most recent discoveries in hematologic care.
Patients in the New Jersey, Connecticut, Maryland, and Washington, D.C. areas who wish to learn more about these advanced blood disorder services and the hematology conditions treated by our team of healthcare providers can contact Regional Cancer Care Associates or schedule an appointment at one of our more than 20 locations today.
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
With care centers in New Jersey, Connecticut, Maryland, Massachusetts and the Washington, D.C., area, thousands of patients each year have come to rely on the expertise, dedication and compassion of Regional Cancer Care Associates.
More than 80 medical oncologists and hematologists affiliated with Regional Cancer Care Associates (RCCA) – one of the nation’s largest networks of oncology specialists — are on the frontlines of the fight against cancer in New Jersey, providing care to well over 100,000 people each year in 19 community-based practices across the Garden State.
The American Cancer Society will host its 43rd annual Diamond Ball Gala on November 24, 2024, at the Westmount Country Club in Woodland Park, NJ.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.
